Sernova Corp SEOVF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.20
- Day Range
- $0.19–0.21
- 52-Week Range
- $0.19–0.72
- Bid/Ask
- $0.18 / $0.25
- Market Cap
- $63.76 Mil
- Volume/Avg
- 34,511 / 23,952
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sernova Corp is a clinical-stage company developing products for the treatment of chronic debilitating diseases. The company is engaged in the research and development of its proprietary Cell Pouch and associated technologies including immune-protected therapeutic cells. The Cell Pouch is is a scalable, implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.sernova.com
Comparables
Valuation
|
Metric
|
SEOVF
|
KROS
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 20.55 |
Price/Book Value | — | 4.16 | 19.85 |
Price/Sales | — | 6,992.78 | 10.66 |
Price/Cash Flow | — | — | 37.30 |
Price/Earnings
SEOVF
KROS
TGTX
Financial Strength
|
Metric
|
SEOVF
|
KROS
|
TGTX
|
|---|---|---|---|
Quick Ratio | 0.58 | 23.73 | 2.76 |
Current Ratio | 0.62 | 24.74 | 3.62 |
Interest Coverage | −935.88 | — | 4.45 |
Quick Ratio
SEOVF
KROS
TGTX
Profitability
|
Metric
|
SEOVF
|
KROS
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −152.26% | −33.58% | 27.97% |
Return on Equity (Normalized) | −284.31% | −36.62% | 73.42% |
Return on Invested Capital (Normalized) | −283.33% | −35.21% | 42.25% |
Return on Assets
SEOVF
KROS
TGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Tlpzkslsmd | Xwms | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jmdjmtthl | Lcrycd | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yrcfrqrmp | Pnrnt | $118.7 Bil | |||
| Moderna Inc
MRNA
| Pgxzqrjrd | Xcgd | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xqfcnmwbv | Rlspkp | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Dhtshmgrt | Vqxt | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Qpthyspz | Kzjp | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Llbpzdv | Dpxkw | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Sjtzdykf | Cfndb | $15.0 Bil | |||
| Incyte Corp
INCY
| Qsmbxpnhc | Xbfzjr | $13.5 Bil |